AEGEAN Trial Demonstrates Benefit and Viability of Novel Perioperative Treatment Approach in NSCLC

John V. Heymach, MD, PhD, expands on the efficacy of perioperative durvalumab in the AEGAN trial, the significance of this unique approach for the non–small cell lung cancer treatment paradigm, and future research examining opportunities to build on or intensify the benefit achieved with this regimen.

Related Keywords

Texas ,United States ,Houston ,Johnv Heymach , ,Serono ,Genentech ,Chugai Pharmaceuticals ,Glaxosmithkline ,Eli Lilly Co ,Cancer Research ,Bristol Myers Squibb ,Novartis ,University Of Texas Md Anderson Cancer Center ,Astrazeneca ,Neck Medical Oncology ,David Bruton Endowed Chair ,Cancer Center ,Mirati Therapeutics ,Eli Lilly ,Jazz Pharmaceutics ,Curio Science ,Blueprint Medicine ,The University Of Texas Md Anderson Cancer Center ,News ,Immunotherapy In Lung Cancer ,Lung Cancer ,Immunotherapy ,Durvalumab ,The Aegan Trial ,